Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Lesofavumab in Healthy Volunteers
NCT02528903Phase 1Completed
- Sponsor
- Genentech
- Start
- Aug 2015
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lesofavumab in influenza B (5 cohorts), sponsored by Genentech. Primary endpoints: Incidence of adverse events up to 120 days, Changes in vital signs up to 120 days and 4 more. Started Aug 2015; status: completed.
02
Drugs
lesofavumab
03
Conditions
influenza B
Beyond the preview
Go deeper on NCT02528903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02528903.